In addition to the many positive vaccine reports in recent days, researchers in the United States are now encouraging us with another positive coronary news: They claim that they have developed a drug that prevents the transmission of the virus. That would be a real breakthrough!
Researchers from Georgia State University in Atlanta, USA, are apparently on their way to a big thing: According to the Italian news agency Ansa in the journal “Nature Microbiology”, they have developed an antiviral drug that can interrupt the transmission of coronavirus. The special property: the active ingredient can be taken orally.
Corona: Molnupiravir can prevent the transmission of viruses
The drug, which has so far only been tested on ferrets, suppresses the reproduction of the virus in the body within 24 hours. So it can not be spread throughout the body.
According to the researchers, the data can also be transferred to humans – the first studies with volunteers are already underway. This would mean that corona-infected people are no longer contagious after taking their medicine called molnupiravir within 24 hours at the latest.
According to the researchers, this can have a multiple effect: it would prevent a serious disease course in infected people, drastically shorten the infection phase and thus quickly take control of local epidemics and reduce the emotional and socio-economic consequences of quarantine.
You may also be interested in: Up to 40 percent affected! Italian researchers report a new corona symptom
The drug is “the first orally available drug that can quickly block Sars-CoV-2 transmission,” said Richard Plemper, one of the researchers involved in the research. Molnupiravir was able to “change the game”.
This is how the researchers tested the drug
But how does it work exactly? The researchers locked several ferrets suffering from Covid-19 along with healthy specific details. Some of the sick animals received molnupiravir, the other placebo.
Subsequent tests showed that the ferrets treated with molnupiravir did not transmit the disease, but the untreated animals infected others with the virus.
Molnupiravir was already used on a test basis during the coronary pandemic
The drug, which is said to work in a similar way to Remdesivir, was originally developed for the treatment of influenza diseases. But as early as April 2020, a study found that molnupiravir can prevent and reduce serious lung damage in corona-infected mice.
The product from the manufacturer Ridgeback Biotherapeutics is currently in phase II / III clinical trials. It will probably take until the middle of next year until it has cleared all the necessary barriers to approval and can be used.